Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Brain Tumor Pathology
Published in: Brain Tumor Pathology 3/2015

01-07-2015 | Original Article

Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma

Authors: Manabu Onishi, Tomotsugu Ichikawa, Kazuhiko Kurozumi, Satoshi Inoue, Tomoko Maruo, Yoshihiro Otani, Kentaro Fujii, Joji Ishida, Yosuke Shimazu, Koichi Yoshida, Hiroyuki Michiue, E. Antonio Chiocca, Isao Date

Published in: Brain Tumor Pathology | Issue 3/2015

Login to get access

Abstract

We have established a pair of animal models (J3T-1 and J3T-2) with different invasive and angiogenic phenotypes, and demonstrated that annexin A2 is expressed at higher levels in J3T-1 than J3T-2 cells. The function of annexin A2 in relation to angiogenesis and invasion was investigated using these models. Stable silencing or overexpression of annexin A2 in J3T-1 and J3T-2 cells (J3T-1shA and J3T-2A cells) was established and used. Thirty human glioblastoma samples were evaluated for expression of annexin A2, vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Immunohistochemical and quantitative reverse-transcription polymerase chain reaction analyses revealed higher expression of annexin A2, VEGF and PDGF in J3T-1 and J3T-2A cells. Cultured J3T-1 and J3T-2A cells exhibited higher adhesive ability to endothelial cells. Histopathological analysis of animal brain tumors revealed that J3T-1 and J3T-2A tumors displayed marked angiogenesis and invasion along the neovasculature, whereas J3T-2 and J3T-1shA tumors exhibited diffuse, infiltrative invasion without angiogenesis. Positive expression of annexin A2 was observed in tumor cells surrounding dilated vessels in 25/30 human glioblastoma specimens. Our results reveal that the phenotype of glioma invasion is closely related to angiogenesis. We identify annexin A2 as a factor regulating angiogenesis and invasion of malignant gliomas.
Literature
1.
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRef
2.
Onishi M, Ichikawa T, Kurozumi K, Date I (2011) Angiogenesis and invasion in glioma. Brain Tumor Pathol 28(1):13–24PubMedCrossRef
3.
Inoue S, Ichikawa T, Kurozumi K et al (2012) Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas. World Neurosurg 78(6):670–682PubMedCrossRef
4.
Maruo T, Ichikawa T, Kanzaki H et al (2013) Proteomics-based analysis of invasion-related proteins in malignant gliomas. Neuropathology 33(3):264–275PubMedCrossRef
5.
Tatenhorst L, Rescher U, Gerke V, Paulus W (2006) Knockdown of annexin 2 decreases migration of human glioma cells in vitro. Neuropathol Appl Neurobiol 32(3):271–277PubMedCrossRef
6.
Onishi M, Ichikawa T, Kurozumi K et al (2013) Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology 33(2):162–174PubMedCrossRef
7.
Godiksen S, Selzer-Plon J, Pedersen ED et al (2008) Hepatocyte growth factor activator inhibitor-1 has a complex subcellular itinerary. Biochem J 413(2):251–259PubMedCrossRef
8.
Nakamori S, Okamoto H, Kusama T et al (1997) Increased endothelial cell retraction and tumor cell invasion by soluble factors derived from pancreatic cancer cells. Ann Surg Oncol 4(4):361–368PubMedCrossRef
9.
Ichikawa T, Tamiya T, Adachi Y et al (2000) In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther 7(1):74–82PubMedCrossRef
10.
11.
Emoto K, Sawada H, Yamada Y et al (2001) Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 21(2B):1339–1345PubMed
12.
Duncan R, Carpenter B, Main LC, Telfer C, Murray GI (2008) Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 98(2):426–433PubMedCentralPubMedCrossRef
13.
Esposito I, Penzel R, Chaib-Harrireche M et al (2006) Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 208(5):673–685PubMedCrossRef
14.
Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC (2006) Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81(2):146–156PubMedCrossRef
15.
Zimmermann U, Woenckhaus C, Pietschmann S et al (2004) Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch 445(4):368–374PubMedCrossRef
16.
Syed SP, Martin AM, Haupt HM, Arenas-Elliot CP, Brooks JJ (2007) Angiostatin receptor annexin II in vascular tumors including angiosarcoma. Hum Pathol 38(3):508–513PubMedCrossRef
17.
Reeves SA, Chavez-Kappel C, Davis R, Rosenblum M, Israel MA (1992) Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma. Cancer Res 52(24):6871–6876PubMed
18.
Roseman BJ, Bollen A, Hsu J, Lamborn K, Israel MA (1994) Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res 6(12):561–567PubMed
19.
Iwadate Y, Sakaida T, Hiwasa T et al (2004) Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 64(7):2496–2501PubMedCrossRef
20.
Rescher U, Gerke V (2004) Annexins–unique membrane binding proteins with diverse functions. J Cell Sci 117(Pt 13):2631–2639PubMedCrossRef
21.
Sharma MC, Sharma M (2007) The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des 13(35):3568–3575PubMedCrossRef
22.
Tressler RJ, Updyke TV, Yeatman T, Nicolson GL (1993) Extracellular annexin II is associated with divalent cation-dependent tumor cell-endothelial cell adhesion of metastatic RAW117 large-cell lymphoma cells. J Cell Biochem 53(3):265–276PubMedCrossRef
23.
Jung Y, Wang J, Song J et al (2007) Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood 110(1):82–90PubMedCentralPubMedCrossRef
24.
Bao H, Jiang M, Zhu M, Sheng F, Ruan J, Ruan C (2009) Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol 90(2):177–185PubMedCrossRef
25.
Zhao SH, Pan DY, Zhang Y, Wu JH, Liu X, Xu Y (2010) Annexin A2 promotes choroidal neovascularization by increasing vascular endothelial growth factor expression in a rat model of argon laser coagulation-induced choroidal neovascularization. Chin Med J (Engl) 123(6):713–721
26.
Zagzag D, Amirnovin R, Greco MA et al (2000) Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80(6):837–849PubMedCrossRef
27.
de Groot JF, Fuller G, Kumar AJ et al (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12(3):233–242PubMedCentralPubMedCrossRef
28.
Sun H, Guo D, Su Y, Yu D, Wang Q et al (2014) Hyperplasia of pericytes is one of the main characteristics of microvascular architecture in malignant glioma. PLoS One 9(12):e114246PubMedCentralPubMedCrossRef
29.
Kesavan K, Ratliff J, Johnson EW et al (2010) Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem 285(7):4366–4374PubMedCentralPubMedCrossRef
Metadata
Title
Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma
Authors
Manabu Onishi
Tomotsugu Ichikawa
Kazuhiko Kurozumi
Satoshi Inoue
Tomoko Maruo
Yoshihiro Otani
Kentaro Fujii
Joji Ishida
Yosuke Shimazu
Koichi Yoshida
Hiroyuki Michiue
E. Antonio Chiocca
Isao Date
Publication date
01-07-2015
Publisher
Springer Japan
Published in
Brain Tumor Pathology / Issue 3/2015
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-015-0216-6

Other articles of this Issue 3/2015

Brain Tumor Pathology 3/2015 Go to the issue

Original Article

Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas

Case Report

Findings from positron emission tomography and genetic analyses for cerebellar liponeurocytoma

Original Article

High thioredoxin reductase 1 expression in meningiomas undergoing malignant progression

Original Article

The density of microvessels positive for Wilms’ tumour-1 protein (WT-1) is an independent predictor of recurrence risk in meningiomas

Original Article

Effect of Notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma

Case Report

Familial schwannomatosis with a germline mutation of SMARCB1 in Japan